ArticleJournal of cachexia, sarcopenia and muscle2012
Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.
Article in Journal of cachexia, sarcopenia and muscle, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Pooled it
- Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.Journal of advanced research · 2026Article
- Resveratrol reduces muscle atrophy and stress pathway activation in a combined disuse-hypoxia-mouse model.Frontiers in pharmacology · 2026Article
- The role of adipose tissue in critical illness-induced skeletal muscle wasting-new considerations for treatment approaches.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Review
- Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis.European journal of heart failure · 2025Article
- Article
- Metabolic dysfunction-associated steatotic liver disease: an emerging comorbidity in COPD.Therapeutic advances in chronic disease · 2025Review
- Strategy for drug repurposing in fibroadipogenic replacement during muscle wasting: application to duchenne muscular dystrophy.Frontiers in cell and developmental biology · 2025Article
- Co-morbid sarcopenia and low bone mineral density in young paediatric cancer survivors.Journal of cachexia, sarcopenia and muscle · 2024Article
- Effect of Isoflavone on Muscle Atrophy in Ovariectomized Mice.Nutrients · 2024Article
- Causal influence of muscle weakness on cardiometabolic diseases and osteoporosis.Scientific reports · 2023Article
- Exercise therapy for sarcopenia and diabetes.World journal of diabetes · 2023Review
- Cellular interplay in skeletal muscle regeneration and wasting: insights from animal models.Journal of cachexia, sarcopenia and muscle · 2023Review
- The role of proteasome in muscle wasting of experimental arthritis.Advances in rheumatology (London, England) · 2023Article
- Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies.Frontiers in physiology · 2022Review
- Exercise Therapy for People With Sarcopenic Obesity: Myokines and Adipokines as Effective Actors.Frontiers in endocrinology · 2022Review
- Maternal protein restriction changes structural and metabolic gene expression in the skeletal muscle of aging offspring rats.Histology and histopathology · 2021Article
- Two Types of Mouse Models for Sarcopenia Research: Senescence Acceleration and Genetic Modification Models.Journal of bone metabolism · 2021Article
- BST204 Protects Dexamethasone-Induced Myotube Atrophy through the Upregulation of Myotube Formation and Mitochondrial Function.International journal of environmental research and public health · 2021Article
- Role of Protein Arginine Methyltransferases and Inflammation in Muscle Pathophysiology.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in our understanding of the biology of muscle, and how anabolic and catabolic stimuli interact to control muscle mass and function, have led to new interest in the pharmacological treatment of muscle wasting. Loss of muscle occurs as a consequence of several chronic diseases (cachexia) as well as normal aging (sarcopenia). Although many negative regulators [Atrogin-1, muscle ring finger-1, nuclear factor-kappaB (NF-κB), myostatin, etc.] have been proposed to enhance protein degradation during both sarcopenia and cachexia, the adaptation of mediators markedly differs among these conditions. Sarcopenic and cachectic muscles have been demonstrated to be abundant in myostatin- and apoptosis-linked molecules. The ubiquitin-proteasome system (UPS) is activated during many different types of cachexia (cancer cachexia, cardiac heart failure, chronic obstructive pulmonary disease), but not many mediators of the UPS change during sarcopenia. NF-κB signaling is activated in cachectic, but not in sarcopenic, muscle. Some studies have indicated a change of autophagic signaling during both sarcopenia and cachexia, but the adaptation remains to be elucidated. This review provides an overview of the adaptive changes in negative regulators of muscle mass in both sarcopenia and cachexia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.